Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: A phase II trial in Japan

Journal of Chemotherapy

Volumn 25, Issue 1, 2013, Pages 41-48

  Kudawara, Ikuo ^a   Aoki, Yasuaki ^b   Ueda, Takafumi ^a   Araki, Nobuhito ^c   Naka, Norifumi ^d   Nakanishi, Hirofumi ^e   Matsumine, Akihiko ^f   Ieguchi, Makoto ^g   Mori, Shigeki ^h   Myoui, Akira ^d   Kuratsu, Shigeyuki ⁱ   Hashimoto, Nobuyuki ^d   Yoshikawa, Hideki ^d  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b HIMEJI RED CROSS HOSPITAL   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Sent Maria Hospital   (Japan)

^f MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g YODOGAWA CHRISTIAN HOSPITAL   (Japan)

^h KAWACHI GENERAL HOSPITAL   (Japan)

ⁱ Bell Land General Hospital   (Japan)

Author keywords

Chemotherapy; Ifosfamide; Limb salvage surgery; Osteosarcoma

Indexed keywords

BICARBONATE; CISPLATIN; DOXORUBICIN; ELECTROLYTE; FOLINATE CALCIUM; FUROSEMIDE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MANNITOL; METHOTREXATE; UBIDECARENONE;

ACIDOSIS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOLESCENT; ADULT; ALOPECIA; ARTICLE; BIOPSY; BONE GRAFT; BONE SCINTISCANNING; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE FREE INTERVAL; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; FRACTURE; GRAFT FAILURE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INFANT; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OTOTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PSEUDOMEMBRANOUS COLITIS; SCHOOL CHILD; X RAY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; INFANT; INFANT, NEWBORN; JAPAN; LIMB SALVAGE; MALE; METHOTREXATE; NEOADJUVANT THERAPY; OSTEOSARCOMA; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873170055     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000055     Document Type: Article

References (41)

1. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600-6.
2. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5:21-6.
3. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163-77.
4. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976;37:1-11.
5. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;48:1221-30.
6. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
7. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian sarcoma group study. J Clin Oncol. 1991;9:1766-75.
8. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the children's cancer group. J Clin Oncol. 1997;15:76-84.
9. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T-12) protocol. J Clin Oncol. 1998;16:2452-8.
10. Lewis IJ, Weeden S, Machin D, Stark D, Craft AW. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. J Clin Oncol. 2000;18:4028-37.
11. Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, Fink K, et al. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol. 2003;10:498-507.
12. Aljubran AH, Griffin A, Pintilie M, Blackstein M. Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases. Ann Oncol 2009;20:1136-41.
13. The incidence of bone tumors in Japan. JOA Musculoskeletal Tumor Committee. Tokyo: National Cancer Center; 1995
14. Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer. 1997;79:411-5.
15. Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, et al. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 2009;14:397-404
16. Marti C, Kroner T, Remagen W, Berchtold W, Cserhati M, Varini M. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep. 1985;69:115-7.
17. Pratt CB, Horowitz ME, Meyer WH, Etcubanas E, Thompson EI, Douglass EC, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987;71:131-5
18. Araki N, Myoui A, Kuratsu S, Hashimoto N, Inoue T, Kudawara I, et al. Intraoperative extracorporeal autogeneous irradiated bone grafts in tumor surgery. Clin Orthop Relat Res. 1999;368:196-206.
19. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;286:241-6.
20. Bacci G, Picci P, Avella M, Dallari D, Ferrari S, Prasad R, et al. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively. J Chemother. 1990;2:127-35.
21. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, et al. Long-term results of the co-operative German-Austrian Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893-9.
22. Winkler K, Bielack S, Delling G, Salzer-Kuntschik M, Kotz R, Greenshaw C, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer. 1990;66:1703-10.
23. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfurst C, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trail (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-37.
24. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Instituto Ortopedico Rizzoli according to the Instituto Orthopedico Rizzoli/Osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-27.
25. Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488-94.
26. Chawla SP, Rosen G, Lownbraun S, Morton D, Eilber F. Role of high dose ifosphamide (HDI) in recurrent osteosarcoma. Proc Am Soc Clin Oncol. 1990;9:310.
27. Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol. 1993;31(Suppl 2):174-9.
28. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose response and schedule dependence. J Clin Oncol. 1997;15:2378-84.
29. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845-52.
30. Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, et al. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 2002;14:198-206.
31. Bacci G, Forni C, Ferrari S, Longhi A, Bertoni F, Mercuri M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity. Intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol. 2003;25:845-53.
32. Smeland S, Bruland OS, Hjorth L, Brosjo O, Bjerkehagen B, Osterlundh G, et al. Results of the Scandinavian sarcoma group XIV protocol for classical osteosarcoma. 63 patients with a minimum follow-up of 4 years. Acta Orthop Scand. 2011;82:211-6.
33. Bielack SS, Kemdf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-90.
34. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154-61.
35. Wunder JS, Gokgoz N, Parkes R, Bull SB, Eskandarian S, Davis AM, et al. TP53 mutations and outcome in osteosar coma: a prospective, multicenter study. J Clin Oncol. 2005;23:1483-90.
36. Eselgrim M, Grunert H, Kuhne T, Zoubek A, Kevric M, Burger H, et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) Trials. Pediatr Blood Cancer. 2006;47:42-50
37. Lewis IJ, Nooji MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112-28.
38. EURAMOS I Trial. 2006. Available: http://www.ctu.mrc.ac.uk/euramos/
39. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-11.
40. Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574-80.
41. Imran H, Enders F, Krailo M, Sim F, Okuno S, Hawkins D, et al. Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. J Bone Joint Surg Am. 2009;91:604-12.